Sign up with

Already have an account? Log in here

Need some help?
Talk to us at +91 7670800001

Development of CAIX-Targeting Radioligands to Improve Tumor Retention at centredtud

, , Belgium -

Full Time

Start Date

Immediate

Expiry Date

21 Mar, 26

Salary

0.0

Posted On

21 Dec, 25

Experience

0 year(s) or above

Remote Job

Yes

Telecommute

Yes

Sponsor Visa

Skills

Organic Synthesis, Molecular Design, Radiolabeling, Ligand Development, Tumor Retention, Molecular Modeling, Chelators, Small Molecules, Cancer Research, Theranostics, Radionuclide Therapy, Hypoxic Tumors, Structure Optimization, Library Design, Innovative Chemistry, Next-Generation Radiotheranostics

Industry

Research Services

Description

Theranostics is transforming precision oncology by integrating diagnosis and therapy in one molecular platform. While compounds such as [¹⁷⁷Lu]Lu-DOTATATE and [¹⁷⁷Lu]Lu-PSMA-617 have proven the potential of targeted radionuclide therapy, novel ligand scaffolds are needed to expand its reach across cancer types. This PhD project focuses on developing innovative small molecules targeting carbonic anhydrase IX (CAIX), a protein highly expressed in hypoxic tumors but largely absent from healthy tissues. The candidate will design and synthesize a library of CAIX-binding ligands guided by molecular modeling, optimize their structures for selectivity and tumor retention, and conjugate the most promising candidates to chelators for radiolabeling with ¹⁷⁷Lu or ¹⁶¹Tb. This chemistry-driven project offers an exciting opportunity to apply advanced organic synthesis and molecular design to the development of next-generation radiotheranostics.

Responsibilities

The candidate will design and synthesize a library of CAIX-binding ligands and optimize their structures for selectivity and tumor retention. They will also conjugate promising candidates to chelators for radiolabeling with ¹⁷⁷Lu or ¹⁶¹Tb.